Stock comparison
Harmony Biosciences Holdings
Soleno Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
SLNO
Soleno Therapeutics
Market cap
$2.76B
Sector
Healthcare
Overall winner
Soleno Therapeutics SLNO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | SLNO | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 57C | HRMY |
| Benjamin Graham | 60C | 66D | SLNO |
| Philip Fisher | 75B | 69C | HRMY |
| Peter Lynch | 62C | 58C | HRMY |
| Joel Greenblatt | 28F | 62C | SLNO |
| Charlie Munger | 62C | 63D | SLNO |
| Terry Smith | 67B | 66B | HRMY |
Side-by-side metrics
| Metric | HRMY | SLNO |
|---|---|---|
| Market cap | $1.75B | $2.76B |
| P/E (TTM) | 11.8x | 28.7x |
| EV/EBIT | 6.4x | 176.1x |
| ROIC (TTM) | 12.5% | 15.35% |
| Gross margin | 76.55% | 98.63% |
| Net margin | 16.2% | 33.7% |
| Revenue CAGR 5y | 29.85% | - |
| EPS CAGR 5y | 46.45% | - |
| Debt / Equity | 0.2x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 176.1x+96%
- P/E (TTM)11.8xvs 28.7x+59%
SLNO leads on
- Debt / Equity0.0xvs 0.2x+96%
- Net margin33.7%vs 16.2%+52%
- Market cap$2.76Bvs $1.75B+37%
- Gross margin98.63%vs 76.55%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.